Mersana Therapeutics Inc (MRSN) - Net Assets
Based on the latest financial reports, Mersana Therapeutics Inc (MRSN) has net assets worth $-59.54 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($62.69 Million) and total liabilities ($122.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Mersana Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-59.54 Million |
| % of Total Assets | -94.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | -104.17% |
| 10-Year Change | N/A |
| Growth Volatility | 300.76 |
Mersana Therapeutics Inc - Net Assets Trend (2015–2024)
This chart illustrates how Mersana Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Mersana Therapeutics Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Mersana Therapeutics Inc (2015–2024)
The table below shows the annual net assets of Mersana Therapeutics Inc from 2015 to 2024. For live valuation and market cap data, see Mersana Therapeutics Inc (MRSN) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-9.51 Million | -125.77% |
| 2023-12-31 | $36.90 Million | -59.91% |
| 2022-12-31 | $92.06 Million | -24.38% |
| 2021-12-31 | $121.74 Million | -46.63% |
| 2020-12-31 | $228.09 Million | +191.23% |
| 2019-12-31 | $78.32 Million | +790.48% |
| 2018-12-31 | $8.79 Million | -87.43% |
| 2017-12-31 | $69.99 Million | +225.85% |
| 2016-12-31 | $-55.62 Million | -30.28% |
| 2015-12-31 | $-42.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mersana Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 85008200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | % |
| Other Comprehensive Income | $10.00K | % |
| Other Components | $886.02 Million | % |
| Total Equity | $-9.51 Million | 100.00% |
Mersana Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Mersana Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Komplett AS
OL:KOMPL
|
$145.39 Million |
|
GEVORKYAN as
PR:GEV
|
$145.41 Million |
|
Trada Maritime Tbk
JK:TRAM
|
$145.45 Million |
|
Serviceware SE
F:SJJ
|
$145.47 Million |
|
Wam Strategic Value Ltd
AU:WAR
|
$145.29 Million |
|
PRECIA SA EO -50
F:P1E0
|
$145.26 Million |
|
Fwusow Industry Co Ltd
TW:1219
|
$145.14 Million |
|
Lima Dua Lima Tiga PT
JK:LUCY
|
$145.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mersana Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 36,904,000 to -9,509,000, a change of -46,413,000 (-125.8%).
- Net loss of 69,192,000 reduced equity.
- Share repurchases of 486,000 reduced equity.
- New share issuances of 5,780,000 increased equity.
- Other comprehensive income decreased equity by 1,000.
- Other factors increased equity by 17,486,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-69.19 Million | -727.65% |
| Share Repurchases | $486.00K | -5.11% |
| Share Issuances | $5.78 Million | +60.78% |
| Other Comprehensive Income | $-1.00K | -0.01% |
| Other Changes | $17.49 Million | +183.89% |
| Total Change | $- | -125.77% |
Book Value vs Market Value Analysis
This analysis compares Mersana Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-61.01 | $29.08 | x |
| 2016-12-31 | $-79.49 | $29.08 | x |
| 2017-12-31 | $77.67 | $29.08 | x |
| 2018-12-31 | $9.55 | $29.08 | x |
| 2019-12-31 | $45.02 | $29.08 | x |
| 2020-12-31 | $92.74 | $29.08 | x |
| 2021-12-31 | $43.12 | $29.08 | x |
| 2022-12-31 | $24.57 | $29.08 | x |
| 2023-12-31 | $7.95 | $29.08 | x |
| 2024-12-31 | $-1.94 | $29.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mersana Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -170.86%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-168.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | -158.59% | 0.72x | 0.00x | $-12.16 Million |
| 2016 | 0.00% | -54.43% | 0.24x | 0.00x | $-8.14 Million |
| 2017 | -55.30% | -220.62% | 0.13x | 1.87x | $-45.71 Million |
| 2018 | -730.61% | -606.54% | 0.13x | 8.93x | $-65.14 Million |
| 2019 | -36.02% | -66.97% | 0.39x | 1.37x | $-36.04 Million |
| 2020 | -38.60% | -10633.45% | 0.00x | 1.20x | $-110.85 Million |
| 2021 | -139.69% | -395488.37% | 0.00x | 1.69x | $-182.23 Million |
| 2022 | -221.83% | -768.26% | 0.08x | 3.63x | $-213.42 Million |
| 2023 | -465.18% | -465.80% | 0.16x | 6.13x | $-175.36 Million |
| 2024 | 0.00% | -170.86% | 0.28x | 0.00x | $-68.24 Million |
Industry Comparison
This section compares Mersana Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mersana Therapeutics Inc (MRSN) | $-59.54 Million | 0.00% | N/A | $145.36 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial.… Read more